used for treatment of patients with type II diabetes [6]. This review examines the current knowledge relating to PPARs' action, ligand binding and tissue distribution. Peroxisome proliferators comprise a group of structurRecent developments regarding the role of PPARs in ally diverse compounds including industrial chemicals and diabetes, insulin resistance, atherosclerosis, inflammapharmaceutical agents that were originally identified as tory disease, hypertension, and cancer, with particular relevance to the kidney will also be discussed.
The genomic organization of the human PPAR␥ gene. Alternative promoter usage and splicing of the three 5Ј exons A1, A2, and B results in three different transcripts and two PPAR␥ protein products (PPAR␥1 and PPAR␥2). Note that transcription from the promoter ␥1 and ␥3 results in same protein of 477 amino acids (PPAR␥1protein) and transcript using the promoter ␥2 encoded a protein of 505 amino acids (PPAR␥2 protein), which has additional 28 amino acids at the N-terminus compared with PPAR␥1 protein.
screening of cDNA library with a probe encoding the All three PPAR isoforms share similar structural and functional organization with other nuclear receptors highly conserved C domain of nuclear hormone receptors [3] . This receptor is now designated PPAR␣. Shortly (Fig. 1) . Four major domains have been identified: A/B, C, D and E/F domain [reviewed in 2, 11]. The N-terminal thereafter, two additional isoforms of PPAR were identified: PPAR␤/␦ and PPAR␥ [7] . To date, no mRNA splice A/B domain differs in both length and predicted amino acid sequence and contains a ligand-independent transvariant for PPAR␣ and PPAR␤/␦ has been identified. In contrast, multiple splicing forms of PPAR␥ mRNA activation domain, termed activation function 1 (AF1). This domain plays an important role in regulating PPAR have been reported in many species including mouse and human [8] [9] [10] . In humans three PPAR␥ transcripts activity through both phosphorylation and interdomain communication [12, 13] . The C domain is comprised of have been reported [9] . These three isotypes of PPAR␥ are derived from a single gene as a result of differential about 70 amino acids and encodes the DNA binding domain (DBD). This domain is responsible for the bindsplicing and alternate promoter usage (Fig. 1) . Each PPAR␥ transcript shares the six 3Ј coding exons, difing of PPAR receptor to peroxisome proliferator response element (PPRE) in the promoter region of target fering only in the 5Ј exons. The 5Ј untranslated region of PPAR␥1 contains exons A1 and A2, while PPAR␥3
genes. The D hinge region is a docking domain for cofactors. The E/F C-terminal region contains two important only contains exon A2. Since none of the 5Ј exons distinguishing PPAR␥1 and PPAR␥3 possess a translation domains. One is the ligand-binding domain (LBD), or E domain, responsible for ligand specificity and activainitiation site, PPAR␥1 and PPAR␥3 mRNAs give rise to identical protein products: PPAR␥1. In contrast, tion of PPAR binding to the peroxisomal proliferator response element (PPRE) with resultant modulation of PPAR␥2 has a ␥2-specific coding exon located between exon A2 and exon 1, yielding 30 additional N-terminal gene expression. This region also has been found to play an important role in dimerization and nuclear localizaamino acids in the PPAR␥2 protein [6, 11] . Due to different promoter usage, each PPAR␥ isoform has a distinct tion. The other is the ligand-dependent activation domain AF-2, or F domain. AF-2 domain located in the expression pattern [9, 10]. C-terminal ␣-helix 12 is critical for both ligand-binding PPAR␣ activators, including hypolipidemic compounds WY-14,643 and clofibrate. Importantly, these compounds and recruitment of PPAR cofactors.
exhibit a good correlation between ability to activate PPAR ligands PPAR␣ and the potency to induce hepatocarcinoma in rodents, suggesting that PPAR␣ is the major molecular Similar to other members of the nuclear receptor famtarget of hepatocarcinogenic peroxisome proliferators in ily, PPARs are ligand-activated transcriptional factors, the liver [15] . that is, modulation of target gene transcription depends PPAR␥ is highly expressed in adipose tissue where it on the binding of the ligands to the receptor. PPARs plays a critical role in adipocyte differentiation. Antidiaform heterodimers with the 9-cis retinoic acid receptor, betic TZD including troglitazone and rosiglitazone pro-RXR␣. Activation of PPAR:RXR␣ by PPAR ligands mote adipocyte differentiation through activation of and/or RXR␣ ligands results in a conformational change PPAR␥ [16] [17] [18] [19] [20] . In vitro, these TZDs have been shown of these receptors, allowing the heterodimers to bind to bind PPAR␥ with a kD of 30 to 10,000 nmol/L [21, 22]. PPREs in target genes and modulate the gene transcrip-A synthetic compound, L-165041, selectively activates tion (Fig. 2) . The divergent amino acid sequence in the PPAR␤/␦ at high affinity (kD ϭ 6 nmol/L) with very LBD of the three PPAR isoforms provides the molecular poor affinity for PPAR␥ and no affinity to PPAR␣ Additional PPAR␣ target genes include apolipoproMoreover, these effects were completely blocked by an antisense oligonucleotide of PPAR␤/␦, suggesting a crititein (apo) I, apo-II and apo C-III. PPAR␣ ligand fibrates decrease apo C-III by activation of PPAR␣, leading to cal role for PPAR␤/␦ in modulating osteoclastic bone resorption. enhanced LPL-mediated catobolism of very low-density lipoprotein (VLDL) particles [99] [100] [101] . In contrast, PPAR␣ PPAR␥ and adipogenesis activation increases plasma levels of HDL and its major constituents, apo A-I and A-II through PPAR/RXR het-PPAR␥ has been the most extensively investigated PPAR isoform. The receptor has been cloned from many erodimers [79, 102] . These effects, together with negative regulation of apo C-III, contribute to the hypolipidemic species and identified as the isoform most highly expressed in adipose tissues. The expression of adipocyte effects of fibrates. Based on these observations, PPAR␣ is a critical player in lipid catabolism, including peroxifatty acid binding protein (aP2), as well as many other adipose target genes including lipoprotein lipase (LPL), somal and mitochondrial oxidation, microsomal -oxidation, ketogenesis, and lipid transport.
fatty acid translocase (FAT), fatty acid transport protein (FATP), ACS, malic enzyme (ME), insulin-dependent PPAR␤/␦ in development, fertility, bone formation glucose transporter (GLUT4) and c-Cbl-associated proand lipid metabolism tein (CAP), are activated by PPAR␥ ligands [49, 86] . This array of PPAR␥ target genes is consistent with the While it has been widely accepted that PPAR␣ and PPAR␥ are two key players in lipid metabolism, it now role of PPAR␥ in lipid accumulation. Moreover, a gainof-function study showed that forced ectopic expression appears likely that PPAR␤/␦ is also involved in lipid homeostasis. A recent study by Leibowitz et al showed of PPAR␥ in fibroblasts produced a marked stimulation adipogenesis in the presence of PPAR␥ activators [107, that PPAR␤/␦ specific agonist L-165041 significantly increased high-density lipoprotein (HDL)-cholesterol lev-108]. This observation was confirmed further in vivo. Mutation of Pro115Gln in PPAR␥ destroys a MAP kiels without effects on blood glucose or triglycerides concentration in db/db obese mice. These results suggest that nase target site in Ser112, resulting in increased activity of PPAR␥ receptor and severe obesity in humans [63] . PPAR␤/␦ agonists could be a novel therapeutic agents in dyslipidemia [103] .
Conversely, in vitro introduction of a dominant negative PPAR␥ mutant with a defective transactivation domain Ubiquitous expression, poor availability of specific ligands and lack of a connection to clinical disorders have blocked TZD-induced terminal differentiation of human pre-adipocytes [109] . Unfortunately, loss-of-function (gene impeded progress in elucidating the specific function of PPAR␤/␦. PPAR␤/␦ expression is particularly high in knockout) studies of adipogenesis using gene targeting have been hampered by an unexpected requirement of certain developing and adult tissues, such as central nervous system, kidney and placenta [34, 35, 66] . This expres-PPAR␥ for placental development and embryonic lethality [110] . Recently, several lines of evidence supsion pattern indicates a potential function of PPAR␤/␦ in these tissues. For example, PPAR␤/␦ has been found ported the critical role of PPAR␥ in adipogenesis in vivo. Study on mice chimeric for wild-type and PPAR␥-null to be predominant isotype expressed in the uterus during the pre-implantation period in mice [104] . Its expression cells showed that PPAR␥ (Ϫ/Ϫ) embryonic stem (ES) cells fail to contribute to adipose tissues, whereas most was induced in the stroma surrounding the implanting blastocyst and localized in the decidual zone postimplanother organs examined did not require PPAR␥ for proper development [18] . These data support an essentation. Its obligate partner RXR␣ was also highly expressed in endometrial cells and decidua. In addition, tial role for PPAR␥ in fat formation. Similar conclusions were supported in another study using PPAR␥ mutant PGI 2 , an endogenous PPAR␤/␦ ligand, is generated in stromal cells at the site of implantation. More impormice generated by supplementing PPAR␥ null embryos with wild-type placenta, via aggregation with tetraploid tantly, the PPAR␤/␦ agonists such as carbaprostacyclin or L-165041 in combination of 9-cis retinoic acid were embryos [110] . The live-born PPAR␥ null mice were notable for total absence of white and brown adipose able to restore implantation in the COX-2 gene knockout mice, in whom defects in implantation and decidualizatissue (lipodystrophy). Taken together, these data demonstrate that PPAR␥ is required for adipogenesis both in tion were previously reported [104, 105] . These data suggest that PPAR␤/␦ plays an essential role in fertility.
vitro and in vivo. Thus, together with a number of other transcription factor including CAAT/enhancer binding Recently, PPAR␤/␦ has been reported to be the predom-proteins (C/EBPs), sterol regulatory element binding proand mFABP may be responsible, at least in part, for teins (SREBPs) and PPAR␤/␦, PPAR␥ promotes and enhanced insulin sensitivity. TZD PPAR␥ ligands have maintains adipocyte function [19, 86, 111, 112] .
been also shown to ameliorate TNF-␣-induced insulin resistance, suggesting that suppression of TNF-␣ activation also might be involved in favorable effect of TZDs PPARS AND RENAL DISEASE in diabetes and insulin resistance [127, 128] . Beyond a role in adipogenesis, PPARs have been Most recently, a new adipocyte-secreted hormone deslinked to many human diseases including obesity, insulin ignated resistin (for "resistant to insulin") has been proresistance, type II diabetes, atherosclerosis, hypertenposed as a molecular link between obesity and type II sion, inflammation and cancer. Ligands for these recepdiabetes. TZD rosiglitazone markedly reduced resistin's tors have been suggested to have therapeutic potential expression in adipocytes as well as its circulating level. for selected human diseases.
Resistin appears to play a role in pathogenesis of insulin resistance [129, 130] , since administration of neu-PPAR␥, insulin resistance, and type II diabetes tralizing antibody to resistin significantly improved blood glucose and insulin action in mice with diet-induced obeNumerous studies have supported a therapeutic role sity, suggesting that TZD activation of PPAR␥ might for PPAR␥ in the treatment of type II diabetes. TZD increase insulin sensitivity by suppressing the production PPAR␥ ligands including troglitazone (Rezulin), piogliof resistin by adipocytes. tazone (ACTOS) and rosiglatazone (Avandia) are a Despite the successful use of TZDs as antidiabetic relatively new class of oral antidiabetic agents that imdrugs, the specific role of altered PPAR␥ function in the prove all three primary defects in patients with type II pathogenesis of insulin resistance and type II diabetes diabetes, that is, insulin resistance, hyperinsulinemia and remains uncertain. It has long been known that obesity hyperglycemia [113] . Troglitazone significantly reduces plasma glucose, % glycosylated hemoglobin, insulin and is a major risk factor in the development of type II C-peptide level in type II diabetes [113] [114] [115] [116] . Moreover, diabetes. In obese rats, TZDs increase the number of this agent also shows beneficial effects of lipid metabosmall adipocytes and decrease the number of large adipolism, blood pressure and cardiac output [113, 117] . These cytes through adipocyte differentiation induced by effects are generally thought to be mediated by activation PPAR␥ activation [131, 132] . Troglitazone may increase of PPAR␥ and enhanced insulin sensitivity in peripheral insulin sensitivity through these small adipocytes via intissues [118] . In support of this, ligands of RXR␣, the hibition of TNF-␣ expression and decreased plasma lipobligate partner of PPAR␥, also exhibit a glucose-and ids [127] . In humans, loss-of-function mutations of lipid-lowering activity [119] that is additive to a PPAR␥ PPAR␥ share elements of the insulin resistance synagonist [120] . Although TZDs have been successfully drome (insulin resistance, type II diabetes, hypertension used in the treatment of type II diabetes, the relevant and dyslipidemia), but not obesity [133] . In contrast, tissue targets remains undefined. Since PPAR␥ is abunpatients with a gain-of-function mutation of PPAR␥ are dantly expressed in adipose tissues, fat cells have been obese, but have a relatively low level of insulin and implicated as a primary target tissue for TZDs [121] .
increased sensitivity to insulin [63] . These data suggest Arguing against this hypothesis is the observation that that excess PPAR␥ activity contributes to obesity and mice genetically manipulated to delete adipose tissue reduced PPAR␥ activity elicits insulin resistance. Howdevelop severe insulin resistance, and that troglitazone ever, studies on mice heterozygous for the PPAR␥ gene ameliorates hyperinsulinemia and hyperglycemia in this paint a more complex picture [134, 135] . PPAR␥ (ϩ/Ϫ) model as well [122] . This suggests that the insulin-sensimice develop normally, have a normal number and size tizing effects of TZD are independent of effects on adiof adipocytes and show no metabolic defect. However, pose tissues. Another proposed target tissue for TZDs the size of the adipocytes in PPAR␥ (ϩ/Ϫ) mice on a is skeletal muscle, the major site of impaired insulin high-fat diet is much smaller than those in wild-type mice, action in type II diabetes. PPAR␥ has been found to be and PPAR␥ (ϩ/Ϫ) mice unexpectedly exhibit enhanced expressed in skeletal muscle tissue [123] and its expresinsulin sensitivity and reduced weight gain as compared sion is enhanced in type II diabetic patients [60, [124] [125] [126] .
to wild-type mice. In this setting, PPAR␥ may promote The activation of PPAR␥ increases expression of adiposmall adipocyte formation, which is insulin sensitive. On cyte lipid binding protein (ALBP) and muscle fatty acid the other hand, PPAR␥ activation can stimulate hyperbinding protein (mFABP) in this tissue [125] , potentially trophy (large adipocytes) of pre-existing adipocytes, modulating lipid and fatty acid uptake. Fatty acids are which leads to insulin resistance. Taken together, these key regulators of insulin sensitivity. It is well-established data suggest a complex role for PPAR␥ in adiposity and that fatty acids decrease glucose usage in skeletal muscle. PPAR␥-induced increase in fatty acids uptake by ALBP insulin resistance.
PPARs and obesity genes implicated in energy homeostasis, including TNF-␣ and UCPs [127, 155] . These data suggest that multiple Both PPAR␣ and PPAR␥ receptors have been implimechanisms contribute to the pathogenic role of PPAR␥ cated in the pathogenesis of obesity. PPAR␣ agonist in obesity. fibrate treatment has been reported to reduce weight gain in rodents [136, 137] . Moreover, PPAR␣ null mice PPAR␥ and hypertension accumulate more body fat with aging [138, 139] . These Hypertension in Western countries is commonly data suggest that PPAR␣ plays an important role in linked to obesity and insulin resistance [156, 157] . Reobesity. The mechanisms may involve both regulation cently thiazolidinediones (TZDs) have been found not of lipid catabolism and energy expenditure. PPAR␣ has only to sensitize tissue to insulin but also to lower blood been shown to increase the expression of uncoupling pressure in both animals and humans [158] [159] [160] [161] . Studies proteins (UCP-1, UCP-2, and UCP-3), mitochondrial on hyperinsulinemic Watanabe heritable hyperlipidemic inner-membrane transporters responsible for heat gener-(WHHL) rabbits or obese Zucker rats show that the ation through uncoupling proton entry from ATP syn-PPAR␥ ligand troglitazone increases insulin sensitivity thesis [140, 141] . UCPs are important regulators of therand lowers blood pressure [159] [160] [161] . Similarly, troglitamogenesis and body weight regulation. All three UCPs zone has been shown to be effective in ameliorating are abundantly expressed in brown adipose tissue hypertension in patients with type II diabetes [158] . It (BAT), however, each UCP differs in its expression pathas been suggested that the antihypertensive effect of tern in other tissues [142] [143] [144] [145] [146] [147] . UCP-1 is relatively reTZDs is a result of improved insulin resistance, since stricted to brown fat tissue [148] . In contrast, UCP-2 is enhanced insulin sensitivity has been found to be associexpressed in most tissues at varying levels, while UCP-3 ated with lower blood pressure both in diabetic animals is expressed predominantly in skeletal muscle and brown [162] [163] [164] [165] and humans [166] . Direct vascular effects of adipose tissue. Given the wide tissue distribution pattern PPAR␥ also may play a role, since recent studies have of UCP-2 and UCP-3, it was originally thought that they identified PPAR␥ in both endothelium and vascular may contribute more to adaptive thermogenesis than smooth muscle cells [167] [168] [169] [170] [171] . Studies on one-kidney, UCP-1. However, increased rather than decreased exone-clip hypertensive rats, a model not associated with pression of UCP-2 and UCP-3 has been observed after insulin resistance, shows that pioglitazone significantly starvation, a state known to be associated with decreased lowers the blood pressure [172] . It is conceivable that energy expenditure [149, 150] . Furthermore, although vascular expression of PPAR␥ could modulate the retransgenic mice with toxigen-mediated reduction of lease of vasodilator autacoids [173] . Troglitazone has brown fat (UCP-DTA) develop obesity [151] , UCP-1 been reported to dilate peripheral blood vessels both in targeted mice have a defect in adaptive thermogenesis vitro and in vivo in animals [173, 174] and humans [117, but not obesity [142] . Thus, based on these undefined 175]. These effects seem to depend on prostaglandin roles of UCPs in obesity, regulation of PPAR␣ in this synthesis since troglitazone-induced vasorelaxation was setting of disease requires more investigation.
abolished by the prostaglandin synthase inhibitor indoThe role of PPAR␥ in pathogenesis of obesity appears methacin [175] , suggesting that these vasorelaxant effects more clear. As discussed above, PPAR␥ plays a critical are mediated by locally generated prostanoids, possibly role in adipogenesis both in vitro and in vivo. Dysfuncendothelial derived prostacyclin [173] . Other studies sugtion of the PPAR␥ receptor has significant effects on gest that antihypertensive effects of TZDs also involve body fat mass. This has been confirmed both by transdecreased fatty acid levels, blockade of L-type calcium genic studies and human genetic studies [152] . Patients channels and modulation of vascular production of vasowith an activating missense mutation of the PPAR␥2 active peptides including type-C natriuretic peptide, enprotein exhibit accelerated adipocyte differentiation and dothelin, and plasminogen activator inhibitor-1 (PAI-1) develop severe obesity [63] . In contrast, patients with a [176, 177] . Alternatively, PPAR␥ may directly affect vas-PPAR␥2 mutation associated with decreased receptor cular smooth muscle cell (VSMC) tone. Troglitazone has activity exhibit lower body mass and improved insulin been shown to inhibit VSMC proliferation and migration sensitivity [64] . Together with the previously discussed in vitro [40, 168] , as well as following angioplasty [178] . effects of PPAR␥ disruption on adiposity in knockout Finally, PPAR␥ has been identified in collecting ducts mice, these data clearly demonstrate that PPAR␥ plays and glomeruli (abstract; Guan et al, J Am Soc Nephrol a critical role in obesity. These effects on adipocytes may 11:A3381, 2000) [35] . Constitutive expression of PPAR␥ include modulation of leptin-stimulated lipolysis and gluin these segments might have important regulatory efcose utilization. Thiazolidinediones inhibit leptin profects on salt and water absorption. These effects could duction [153] through PPAR␥-dependent PPRE in procontribute to the edema complicating treatment using moter region of the leptin (ob) gene [154] . In addition, TZDs in patients and animals [161, 179, 180] . Taken together, these data suggest that PPAR␥ expression con-PPAR␥ has been also shown to regulate many other tributes to blood pressure regulation through multiple ular mesangial cells (abstract; Guan et al, J Am Soc Nephrol 11:A3381, 2000). It is well established that mesmechanisms.
angial cells play an important role in the progression of PPARs and kidney disease nephropathy. During inflammatory injury or high glucose stimulation, mesangial cells undergo a process of The role of PPAR isoform expression in the kidney is just now being elucidated, All three PPAR isoforms are activation from a quiescent phenotype to a proliferative myofibroblast-like phenotype, characterized by increased expressed in the kidney of many species including humans [35, 69, 72] . PPAR␣ expression predominates in ␣-smooth muscle actin and pro-inflammatory cytokines, as well as enhanced production of extracellular matrix the proximal tubule and thick limb, and could contribute to dietary lipid-induced gene expression of peroxisomal proteins [186] [187] [188] . This phenotypic alteration has been considered a fundamental feature in the development of and mitochondrial ␤-oxidation in these segments [181] . The PPAR␣ agonist clofibrate significantly induced exdiabetic nephropathy and glomerulonephritis. Studies by Asano et al showed that the TZD PPAR␥ ligands, pression of ␤-oxidation enzymes in renal cortex, including long-chain acyl CoA dehydrogenase (LCAD), metroglitazone, and endogenous PPAR␥ ligand, 15dPGJ2, can significantly suppress the production of ␣-smooth dium-chain acyl CoA dehydrogenase (MCAD) and acyl CoA oxidase (ACO). These data suggest that renal muscle actin, indicating that PPAR␥ activation may inhibit de-differentiation of mesangial cells [70] . In addi-PPAR␣ plays a major role in triggering fatty acid utilization and the adaptive response to dietary lipids in the tion, in vitro studies have shown PPAR␥ ligands can significantly inhibit proliferation of mesangial cells in a kidney. Notably, renal PPAR␣ also colocalizes with P450 4 A enzymes, which are known PPAR␣ target genes [93] dose-dependent manner [70] . These data suggest that PPAR␥ activation may reverse the phenotypic change that appear to be involved in blood pressure regulation [182] . Interestingly, clofibrate has been shown to reduce of mesangial cells and induce cell growth arrest and reduction of extracellular matrix production. Therefore, blood pressure in Dahl salt-sensitive rats [183] . These findings suggest that PPAR␣ participates in blood presglomerular PPAR␥ activation could be a therapeutic target for treating diabetic nephropathy. Indeed, troglisure regulation through activation of P450 4 A enzymes in the proximal tubules. In addition, PPAR␣ has also tazone treatment has been shown to ameliorate microalbuminuria both in the streptozotocin-induced diabetic been shown to play an important role in maintaining a sustained balance of energy production/utilization in the rat and type II diabetic patients [189, 190] . In the fa/fa rat, a genetic model of type II diabetes, intervention with kidney through regulating expression of genes involved in fatty acid ␤-oxidation [184] . This effect may contribute troglitazone decreased proteinuria and halted the early onset and progression of mesangial expansion and gloto the observation that PPAR␣ ligands appear to protect kidney from ischemia/reperfusion injury in rats [184] . Mice merulosclerosis [191] . Similarly, pioglitazone and rosiglitazone markedly reduce proteinuria and slow the prolacking the PPAR␣ gene exhibit more severe cortical necrosis and worse kidney function than wild-type control gression of diabetic nephropathy in genetically obese diabetic rats [161, 192] . animals [184] . These findings help to explain the molecular mechanisms by which ischemia/reperfusion leads to supAccumulating evidence suggests that TZDs have direct and beneficial glomerular effects. A recent study in pression of fatty acid ␤-oxidation, and might provide a new therapeutic strategy for ischemic renal injury.
streptozotocin-induced diabetic rat showed that troglitazone was not only able to prevent diabetic glomerular PPAR␥ mRNA is also highly expressed in the kidney, but in contrast to PPAR␣ is predominantly expressed hyperfiltration and albuminuria, but also to reduce mRNA expression of extracellular matrix proteins (fibronectin in collecting ducts, which suggests that this isoform might play a role in systemic water and sodium retention. In and type IV collagen) and TGF-␤1 in diabetic glomeruli. These beneficial effects in insulin-dependent diabetes fact, in both rodents and humans, treatment with TZD PPAR␥ ligands may cause marked fluid retention, edema mellitus suggest that PPAR␥ ligands can protect glomerular function independently of their capacity to increase and hemodilution [161, 179, 180] . Although other mechanisms may be involved, the possibility that collecting duct glucose tolerance. Furthermore, in a nondiabetic glomerulosclerotic model, PPAR␥ ligands were effective in pre-PPAR␥ activation is responsible for water and sodium retention in TZD-treated diabetic patients has not been venting the deterioration of renal function. In a 5/6 ablation model of renal failure, Ma et al recently noted that examined.
Cultured mesangial cells have also been found to extroglitazone treatment significantly reduced proteinuria, serum creatinine level and glomerulosclerosis possibly press PPAR␥ [70]. Interestingly they also may produce a precursor of 15dPGJ2, a putative endogenous PPAR␥ via inhibition of glomerular cell proliferation and reduction of TGF-␤1 expression in glomeruli and renal tubules, ligand [185] . A preliminary report also demonstrates the presence of PPAR␥ in freshly isolated glomeruli, and suggesting a paracrine PPAR␥ system in glomerular mesangial cells (Note added in proof). This is consistent with suggest that a paracrine PPAR␥ system exists in glomer-other studies showing a beneficial effect of troglitazone the IL-1-stimulated release of IL-6 and prostaglandin and expression of cyclooxygenase-2 (COX-2) [199] . Data on glomeruli. Taken together, these studies suggest that TZDs may be used as possible therapeutic agents for suggest that these effects were mediated by inhibition of nuclear factor-B (NF-B) and activator protein-1 diabetic nephropathy and glomerulosclerosis.
Finally, both PPAR␣ and PPAR␥ have potent anti-(AP-1), two ubiquitous transcription factors that transduce the effects of many pro-atherogenic and inflammainflammatory effects in macrophages [42, 193] . It is reasonable to anticipate that PPAR activation might also tory factors [201] [202] [203] . PPAR␣ has also been shown to lower the plasma concentration of fibrinogen, an imporplay a role in renal inflammation, including glomerulonephritis and interstitial nephritis; however, thus far few tant risk factor for cardiovascular disease, both in rat and in human [199, 204] . In addition, PPAR␣ ligands reports have addressed this important issue. A recent preliminary report suggested that the PPAR␥ ligand, effectively increased HDL cholesterol level and decreased the low-density lipoprotein (LDL) cholesterol level in troglitazone, significantly enhanced rather than repressed glomerular expression of MCP-1, a critical cytokine in hyperlipidemic patients, as a result of transcriptional induction of HDL apolipoproteins, apo A-I and apo A-II, recruiting monocytes in glomeruli, in a rat model of mesangioproliferative glomerulonephritis (abstract; Panzer and LPL, and inhibition of hepatic apo C-III production through the PPAR␣ receptor (see above) [4] . et al., J Am Soc Nephrol 11:A2625, 2000). These results raise the possibility that certain PPAR␥ ligands might
Little is known about the role of PPAR␤/␦ in atherosclerosis. Recent evidence has emerged that PPAR␤/␦ promote, rather than inhibit, the progression of glomerulonephritis. If so, PPAR␥ antagonists could provide a novel might be a target for treatment of dyslipidemia since a PPAR␤/␦ ligand increases the HDL-cholesterol level therapeutic approach to renal inflammatory diseases.
[103]. Since hyperlipidemia is a key atherogenic factor, PPARs, inflammation and atheroscerosis the effect of PPAR␤/␦ in increasing HDL-cholesterol may be beneficial in prevention of atherosclerosis. Renovascular stenosis and atheroemboli represent increasingly common disorders contributing to renal dys-PPAR␥ has also been implicated in at least three pathologic processes in atherosclerosis: foam cell differfunction in elderly diabetic patients [194, 195] . PPAR activation also may modify the course of atherosclerosis entiation, inflammatory reaction and cell proliferation. The infiltrating monocytes in the intima of the arterial via effects on inflammation, modulation of lipid accumulation in the arterial wall and altered endothelial funcwall take up oxidized LDL via scavenger receptors (SRAI/II, SR-BI, CD36, etc.), promoting accumulation tion, proliferation of vascular smooth muscle, and foam cell formation. All three PPAR isoforms may modify of intracellular lipids and generation of lipid-laden foam cells [205] . It has been shown that the oxidized LDL the progression of atherosclerosis through multiple mechanisms including modulation of plasma lipoprotein (OxLDL) scavenger receptor CD36 (fat) is under direct control of PPAR␥. PPAR␥ ligand, in combination of concentration, foam cell formation, inflammatory response and pro-atherosclerotic protein level.
RXR␣ agonist LG268, significantly up-regulates the expression of CD36 and the binding of OxLDL in a monoHypolipidemic fibrates (clofibrate and benzofibrate) are potent PPAR␣ agonists proven to be beneficial in cytic cell line [30] . Interestingly, OxLDL contains naturally occurring PPAR␥ ligands (9-HODE and 13-HODE). the prevention of atherosclerosis [196] . Formation of atherosclerotic lesions require recruitment of monocytes Furthermore, in the presence of OxLDL, PPAR␥ expression was markedly induced [206] . This positive feedinto the arterial wall through expression of specific adhesion molecules by endothelial cells. Not only is PPAR␣ back loop could promote atherosclerosis by stimulating the uptake of OxLDL in macrophage/foam cells. Cytoexpressed in human endothelial cells [197] , but its activation decreases the expression of the adhesion molecule kines produced by these activated macrophage/foam cells include M-CSF, IL-1, and TNF-␣, and they initiate VCAM-1 in these cells [198] . Moreover, PPAR␣ has been implicated in inflammatory processes of the atheroinflammation and induce proliferation of VSMCs. In contrast, other effects of PPAR␥ might be beneficial in sclerotic lesion, which is believed to be responsible for disruption of atherosclerotic plaque [199] . PPAR␣-defithe treatment of atherosclerosis. An anti-inflammatory effect of PPAR␥ in monocytes has been described. cient mice show a prolonged response to inflammatory stimuli, suggesting PPAR␣ modulates inflammation PPAR␥ has been shown to reduce cytokine (TNF␣, IL-1, and IL-6) production [42] , probably by inhibiting the [200] . In hyperlipidemic patients, the PPAR␣ ligand fenofibrate, significantly decreased plasma concentrations activity of pro-inflammatory transcription factors such as NF-B, AP-1 and STAT [207] . Other favorable effects of interleukin-6 (IL-6). Anti-inflammatory effects were also observed in cultured vascular smooth muscle cells of PPAR␥ include induction of apoptosis in monocytes [208] , inhibition of proliferation of VSMCs [37, 178], (VSMCs), which participate in plaque formation and postangioplasty re-stenosis. PPAR␣ is functionally acsuppression of metalloproteinase-9 expression [39] , and reduction of plasma triglycerides [209] . On the basis of tive in VSMCs and another ligand, Wy14643, inhibited these data, an important role for PPAR␥ in atheroscleroTreatment of cultured breast cancer cells with troglitazone results in cell growth arrest and promotes differentisis remains uncertain.
Most recently, two studies provide clear evidence that ation [44] . Troglitazone has also been shown to inhibit tumor growth and induce apoptosis in human breast TZDs treatment reduced atherosclerosis in vivo [210, 211] . In the Watanabe heritable hyperlipidemic (WHHL) cancer cells in vitro and in BNX mice [218] . Moreover, another PPAR␥ ligand, GW7845, has been shown to rabbits, troglitazone treatment potently reduced the development of atherosclerotic lesions [210] . Similarly, rodecrease tumor incidence, tumor growth and tumor burden in the NMU induced mammary carcinoma [219] . siglitazone improved atherosclerotic lesions in LDL receptor knockout mice [211] . These data suggest that the These data suggest that PPAR␥ ligands may be used as novel, nontoxic and selective chemotherapeutic agents anti-atherogenic effect of TZDs outweighs its pro-atherogenic effects in vivo. Although it is uncertain whether for human breast cancer. A role for PPAR␥ activation also has been suggested in human transitional bladder the reduction in atherosclerosis following TZD treatment is a direct effect of PPAR␥ activation in macrocancers [46] . PPAR␥ is highly expressed in normal as well as malignant human transitional cell bladder cancer. phages or an indirect effect secondary to improvements of insulin sensitivity, several lines of evidence demonSeveral PPAR␥ ligands (including troglitazone, ciglitazone and 15dPGJ2) significantly inhibit growth in culstrated that PPAR␥ is not required for differentiation of macrophage lineage and the formation of foam cells tured human bladder cancer cells, and this action is associated with induction of cyclin-dependent kinase inhibitors [212, 213] . More importantly, PPAR␥ activation can promote cholesterol removal from human foam cells (p21 and p16) and reduction of cyclin D expression. Importantly, RXR␣ ligands 9-cis retinoic acid and LG100268 through stimulation of ABCA1, a protein involved in cholesterol export [212] . Additionally, PPAR␥ activation exhibited synergy with PPAR␥ ligands in inducing cell death. Anti-tumor effects of PPAR␥ ligands have been also results in the down-regulation of the LDL receptor scavenger SR-A in mouse macrophage [213] PPAR␥ ligands in dyslipidemic patients without type II diabetic patients will be required to clarify the role of mice, a murine model of the human genetic disease familial adenomatous polyposis coli (FAP) [223, 224] . These PPAR␥ in this setting of disease. studies showed that when such mice are treated with PPARs, the cell cycle and cancer troglitazone or with rosiglitazone, they develop an increased frequency of large but not small bowel polyps. Effects of PPARs on renal cell proliferation seem likely, but remain unexplored. All three isoforms of PPAR have
In contrast, troglitazone reduces colon tumor xenograft volume in nude mice [222] . This corresponds to in vitro been suggested to play a role in regulating the cell cycle and in carcinogenesis. PPAR␣, the predominant form studies showing that activation of PPAR␥ results in colon cancer cell cycle arrest (G 1 phase) and differentiation of PPAR in the liver, is involved in the growth promoting and hepatocarcinogenic effect of peroxisome prolifera-
[221], supporting the idea that PPAR␥ activation might be beneficial for human colon cancer as well. The differtors in rodents [15] . However, these rodent data do not appear relevant to humans. No carcinogenic effect of ent effects of troglitazone on polyp formation and cancer growth may reflect important biological differences in peroxisome proliferators has been shown in humans, possibly because of the much lower level of PPAR␣ the two processes. Recently, an important role for PPAR␤/␦ in carcinoexpression in human hepatocytes as a result of exon 6 splicing of PPAR␣ transcripts [53] .
genesis has been proposed [65] . PPAR␤/␦ expression appears to be increased in colorectal cancer and localized Potent effects of PPAR␥ on cell proliferation and cell cycling have been described. PPAR␥ ligands can trigger in dysplastic epithelial cells [225] . The NSAID sulindac, which suppress colorectal tumorigenesis, can antagonize cell cycle arrest in NIH3T3 cells and HIB-1B cells [215] . PPAR␥ ligands can also induce terminal differentiation PPAR␤/␦-activated gene transcription in an in vitro assay system. These findings suggest that NSAIDs may and withdrawal of human liposarcoma cells from the cell cycle [216] . Importantly, TZD PPAR␥ ligands have been inhibit tumorigenesis through inhibition of PPAR␤/␦ activity, thereby contributing to their chemopreventive effound to slow the progression of advanced liposarcoma in humans [217] . Given the expression of PPAR␥ in nonfects [226] , and raise the possibility that PPAR␤/␦ antagonists might have chemopreventive effects in human adipose tissues, the effect of PPAR␥ on human breast cancer, gastric cancer, prostate cancer, colon cancer and colorectal cancer. Specific roles of PPARs in renal cancers and cystic disease remain unexplored. transitional cell bladder cancer have been explored. 
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